Myriad Genetics expects Q3 2024 revenue of $210-212M, reaffirms FY2024 guidance

MYRIAD GENETICS INC

2024-Q3 EPS reported -$0.94 revenue$627,000,000

Preliminary Q3 2024 revenue expected between $210M and $212M.
Full-year 2024 revenue guidance reaffirmed at $835M-$845M.
Divestiture of EndoPredict business in Europe closed on August 1, 2024.
Results are preliminary and unaudited; subject to finalization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.